Renaissance Technologies LLC Sells 67,897 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

Renaissance Technologies LLC reduced its stake in Acelyrin, Inc. (NASDAQ:SLRN – Free Report) by 12.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).

The firm owned 466,921 shares of the company’s stock after selling 67,897 shares during the period. Renaissance Technologies LLC owned approximately 0.47% of Acelyrin worth $1,466,000 at the end of the most recent reporting period.



Several other hedge funds also recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in Acelyrin by 3.5% in the 4th quarter.

Geode Capital Management LLC now owns 1,709,086 shares of the company’s stock worth $5,368,000 after purchasing an additional 57,472 shares during the period. ADAR1 Capital Management LLC boosted its position in shares of Acelyrin by 731.7% in the fourth quarter.

ADAR1 Capital Management LLC now owns 444,967 shares of the company’s stock valued at $1,397,000 after acquiring an additional 391,467 shares during the period. Wellington Management Group LLP purchased a new position in Acelyrin during the fourth quarter valued at approximately $567,000. ExodusPoint Capital Management LP bought a new stake in Acelyrin during the 4th quarter worth approximately $423,000.

Finally, Franklin Resources Inc. lifted its stake in Acelyrin by 36.9% in the 3rd quarter.

Franklin Resources Inc. now owns 128,591 shares of the company’s stock worth $634,000 after purchasing an additional 34,642 shares in the last quarter. 87.

31% of the stock is currently owned by hedge funds and other institutional investors. Acelyrin Stock Up 0.5 %SLRN opened at $2.

18 on Tuesday. The business’s fifty day simple moving average is $2.47 and its 200 day simple moving average is $3.

32. Acelyrin, Inc. has a 52 week low of $1.

85 and a 52 week high of $7.25. The stock has a market cap of $219.

98 million, a PE ratio of -0.89 and a beta of 1.12.

Acelyrin (NASDAQ:SLRN – Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.

86) by $0.07. As a group, equities analysts anticipate that Acelyrin, Inc.

will post -2.53 earnings per share for the current year. Insider Transactions at AcelyrinIn other news, CEO Mina Kim sold 17,986 shares of the business’s stock in a transaction dated Monday, March 17th.

The stock was sold at an average price of $2.74, for a total value of $49,281.64.

Following the completion of the sale, the chief executive officer now owns 671,753 shares of the company’s stock, valued at approximately $1,840,603.22. The trade was a 2.

61 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 13.

60% of the company’s stock. Wall Street Analyst Weigh InSLRN has been the topic of several research analyst reports. HC Wainwright decreased their price target on shares of Acelyrin from $8.

00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. Citigroup lowered their price target on Acelyrin from $6.

00 to $3.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock.

According to data from MarketBeat.com, Acelyrin presently has an average rating of “Hold” and an average price target of $9.60.

Get Our Latest Stock Report on AcelyrinAcelyrin Company Profile (Free Report)Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.Featured StoriesFive stocks we like better than AcelyrinStock Dividend Cuts Happen Are You Ready?Best Defense Stocks in 2025.

.. So FarUsing the MarketBeat Stock Split CalculatorAlphabet Rebounds After Strong Earnings and Buyback AnnouncementInsider Trading – What You Need to KnowCould Selling Taiwan Semiconductor Be Buffett’s Biggest Regret?Want to see what other hedge funds are holding SLRN? Visit HoldingsChannel.

com to get the latest 13F filings and insider trades for Acelyrin, Inc. (NASDAQ:SLRN – Free Report)..